Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox

Progress in Lipid Research

Volumn 58, Issue , 2015, Pages 51-75

  Llona Minguez, Sabin ^a   Ghassemian, Artin ^b   Helleday, Thomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Agonist; Antagonist; Cancer; GPCR; Idiopathic pulmonary fibrosis; Lysophosphatidic acid; Small molecule; Systemic sclerosis

Indexed keywords

A 2058; AM 095; AM 966; BENZAMIDE DERIVATIVE; BMS 986020; DEBIO 0719; GRI 977143; KI 16425; LYSOPHOSPHATIDIC ACID 1; LYSOPHOSPHATIDIC ACID 2; LYSOPHOSPHATIDIC ACID 4; LYSOPHOSPHATIDIC ACID 5; LYSOPHOSPHATIDIC ACID 6; LYSOPHOSPHATIDIC ACID DERIVATIVE; LYSOPHOSPHATIDIC ACID RECEPTOR; NSC 161613; NSC 47091; SAR 100842; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; LIGAND; LYSOPHOSPHOLIPID;

ANTINEOPLASTIC ACTIVITY; BALANCE DISORDER; BIOLOGICAL ACTIVITY; BREAST CANCER; CELL MOTILITY; DIARRHEA; DOWN REGULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; HEADACHE; HUMAN; KIDNEY FIBROSIS; LUNG FIBROSIS; MELANOMA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; PHARMACOLOGY;

ANIMALS; HUMANS; LIGANDS; LYSOPHOSPHOLIPIDS; PHARMACOLOGICAL PHENOMENA; RECEPTORS, LYSOPHOSPHATIDIC ACID;

EID: 84924169659     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2015.01.004     Document Type: Review

References (158)

1. J.W. Choi, D.R. Herr, K. Noguchi, Y.C. Yung, C.-W. Lee, and T. Mutoh LPA receptors: subtypes and biological actions Annu Rev Pharmacol Toxicol 50 2010 157 186
2. T.M. McIntyre, A.V. Pontsler, A.R. St.Silva, A. Hilaire, Y. Xu, and J.C. Hinshaw Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist Proc Natl Acad Sci U S A 100 2003 131 136
3. A.L. Parrill, and G. Tigyi Integrating the puzzle pieces: the current atomistic picture of phospholipid-G protein coupled receptor interactions Biochim Biophys Acta 1831 2013 2 12
4. J.H. Hecht, J.A. Weiner, S.R. Post, and J. Chun Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex J Cell Biol 135 1996 1071 1083
5. S. An, T. Bleu, O.G. Hallmark, and E.J. Goetzl Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid J Biol Chem 273 1998 7906 7910
6. K. Bandoh, J. Aoki, H. Hosono, S. Kobayashi, T. Kobayashi, and K. Murakami-Murofushi Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid J Biol Chem 274 1999 27776 27785
7. K. Noguchi, S. Ishii, and T. Shimizu Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family J Biol Chem 278 2003 25600 25606
8. C.-W. Lee, R. Rivera, S. Gardell, A.E. Dubin, and J. Chun GPR92 as a New G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5 J Biol Chem 281 2006 23589 23597
9. K. Yanagida, K. Masago, H. Nakanishi, Y. Kihara, F. Hamano, and Y. Tajima Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6 J Biol Chem 284 2009 17731 17741
10. K. Yanagida, and S. Ishii Non-Edg family LPA receptors: the cutting edge of LPA research J Biochem 150 2011 223 232
11. J.M. Gerrard, S.E. Kindom, D.A. Peterson, J. Peller, K.E. Krantz, and J.G. White Lysophosphatidic acids. Influence on platelet aggregation and intracellular calcium flux Am J Pathol 96 1979 423 438
12. A. Tokumura, K. Fukuzawa, S. Yamada, and H. Tsukatani Stimulatory effect of lysophosphatidic acids on uterine smooth muscles of non-pregant rats Arch Int Pharmacodyn Ther 245 1980 74 83
13. A. Tokumura, K. Fukuzawa, and H. Tsukatani Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species Lipids 13 1978 572 574
14. E.J. Van Corven, A. Van Rijswijk, K. Jalink, R.L. Van Der Bend, W.J. Van Blitterswijk, and W.H. Moolenaar Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts dependence on acyl-chain length and inhibition by suramin Biochem J 281 1992 163 170
15. F. Hao, M. Tan, X. Xu, J. Han, D.D. Miller, and G. Tigyi Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA1, p42 and p38α Biochim Biophys Acta 1771 2007 883 892
16. G. Tigyi Aiming drug discovery at lysophosphatidic acid targets Br J Pharmacol 161 2010 241 270
17. Y. Kihara, M. Maceyka, S. Spiegel, and J. Chun Lysophospholipid receptor nomenclature review: IUPHAR review 8 Br J Pharmacol 171 2014 3575 3594
18. A. Tokumura A family of phospholipid autacoids: occurrence, metabolism and bioactions Prog Lipid Res 34 1995 151 184
19. A. Tokumura, E. Majima, Y. Kariya, K. Tominaga, K. Kogure, and K. Yasuda Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase J Biol Chem 2002
20. M. Umezu-Goto, Y. Kishi, A. Taira, K. Hama, N. Dohmae, and K. Takio Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production J Cell Biol 158 2002 227 233
21. A.S. Houben, and W. Moolenaar Autotaxin and LPA receptor signaling in cancer Cancer Metastasis Rev 30 2011 557 565
22. S. Okudaira, H. Yukiura, and J. Aoki Biological roles of lysophosphatidic acid signaling through its production by autotaxin Biochimie 92 2010 698 706
23. T. Akira, H. Kengo, F. Kenji, and T. Hiroaki Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma Biochim Biophys Acta 875 1986 31 38
24. A. Tokumura, K. Fukuzawa, Y. Akamatsu, S. Yamada, T. Suzuki, and H. Tsukatani Identification of vasopressor phospholipid in crude soybean lecithin Lipids 13 1978 468 472
25. A. Tokumura, K. Fukuzawa, J. Isobe, and H. Tsukatani Lysophosphatidic acid-induced aggregation of human and feline platelets - structure-activity relationship Biochem Biophys Res Commun 99 1981 391 398
26. A. Tokumura, T. Kume, K. Fukuzawa, and H. Tsukatani Cardiovascular effects of lysophosphatidic acid and its structural analogs in rats J Pharmacol Exp Ther 219 1981 219 224
27. A. Tokumura, T. Maruyama, K. Fukuzawa, and H. Tsukatani Effects of lysophosphatidic acids and their structural analogs on arterial blood-pressure of cats Drug Res 35-1 1985 587 592
28. I. Ishii, N. Fukushima, X. Ye, and J. Chun Lysophospholipid receptors: signaling and biology Annu Rev Biochem 73 2004 321 354
29. J.J. Contos, I. Ishii, and J. Chun Lysophosphatidic acid receptors Mol Pharmacol 58 2000 1188 1196
30. N. Fukushima, I. Ishii, J.J. Contos, J.A. Weiner, and J. Chun Lysophospholipid receptors Annu Rev Pharmacol Toxicol 41 2001 507 534
31. A. Mukherjee, J. Wu, Y. Gong, and X. Fang Lysophosphatidic acid receptors in cancer. Lysophospholipid receptors 2013 John Wiley & Sons, Inc. [p. 661-79]
32. K. Hama, J. Aoki, M. Fukaya, Y. Kishi, T. Sakai, and R. Suzuki Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1 J Biol Chem 279 2004 17634 17639
33. A. Boucharaba, C.M. Serre, J. Guglielmi, J.C. Bordet, P. Clezardin, and O. Peyruchaud The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases Proc Natl Acad Sci U S A 103 2006 9643 9648
34. M. Komachi, K. Sato, M. Tobo, C. Mogi, T. Yamada, and H. Ohta Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo Cancer Sci 103 2012 1099 1104
35. M.M. Murph, J. Hurst-Kennedy, V. Newton, D.N. Brindley, and H. Radhakrishna Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells Mol Cancer Res 5 2007 1201 1211
36. R. Guo, E.A. Kasbohm, P. Arora, C.J. Sample, B. Baban, and N. Sud Expression and function of lysophosphatidic acid LPA(1) receptor in prostate cancer cells Endocrinology 147 2006 4883 4892
37. J.P. Pradere, J. Klein, S. Gres, C. Guigne, E. Neau, and P. Valet LPA1 receptor activation promotes renal interstitial fibrosis J Am Soc Nephrol 18 2007 3110 3118
38. A.M. Tager, P. LaCamera, B.S. Shea, G.S. Campanella, M. Selman, and Z. Zhao The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat Med 14 2008 45 54
39. J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, R.A. Bundey, and P.C. Prodanovich A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model Br J Pharmacol 160 2010 1699 1713
40. J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, A.R. Broadhead, and G. Bain Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist J Pharmacol Exp Ther 336 2011 693 700
41. F.V. Castelino, J. Seiders, G. Bain, S.F. Brooks, C.D. King, and J.S. Swaney Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma Arthritis Rheum 63 2011 1405 1415
42. C. Roberts, P. Winter, C.S. Shilliam, Z.A. Hughes, C. Langmead, and P.R. Maycox Neurochemical changes in LPA(1) receptor deficient mice - a putative model of schizophrenia Neurochem Res 30 2005 371 377
43. B. Anliker, J.W. Choi, M.-E. Lin, S.E. Gardell, R.R. Rivera, and G. Kennedy Lysophosphatidic acid (LPA) and its receptor, LPA(1), influence embryonic schwann cell migration, myelination, and cell-to-axon segregation Glia 61 2013 2009 2022
44. M. Balood, H. Zahednasab, B. Siroos, S.A. Mesbah-Namin, S. Torbati, and M.H. Harirchian Elevated serum levels of lysophosphatidic acid in patients with multiple sclerosis Hum Immunol 75 2014 411 413
45. A. Nieto-Posadas, G. Picazo-Juárez, I. Llorente, A. Jara-Oseguera, S. Morales-Lázaro, and D. Escalante-Alcalde Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site Nat Chem Biol 8 2012 78 85
46. M. Inoue, M.H. Rashid, R. Fujita, J.J. Contos, J. Chun, and H. Ueda Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling Nat Med 10 2004 712 718
47. H. Ueda Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms Pharmacol Ther 109 2006 57 77
48. M. Inoue, L. Ma, J. Aoki, J. Chun, and H. Ueda Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain Mol Pain 4 2008 6
49. E. Kanan, H. Kondo, J. Shishikura, M. Takahashi, K. Sakamoto, and T. Soga Benzyl-12b-methyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine derivatives as LPA receptor agonists 2008 Astellas Pharma Inc. Japan [JP2008297278A]
50. S. Nakade, and D. Fukushima Remedies for urinary diseases comprising lysophosphatidic acid receptor controlling agents 2002 Ono Pharmaceutical Co., Ltd Japan [WO2002062389A1]
51. Y. Miyabe, C. Miyabe, Y. Iwai, A. Takayasu, S. Fukuda, and W. Yokoyama Necessity of lysophosphatidic acid receptor 1 for development of arthritis Arthritis Rheum 65 2013 2037 2047
52. S.A. Karagiosis, and N.J. Karin Lysophosphatidic acid induces osteocyte dendrite outgrowth Biochem Biophys Res Commun 357 2007 194 199
53. Y.B. Liu, Y. Kharode, P.V. Bodine, P.J. Yaworsky, J.A. Robinson, and J. Billiard LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4 J Cell Biochem 109 2010 794 800
54. I. Gennero, S. Laurencin-Dalicieux, F. Conte-Auriol, F. Briand-Mesange, D. Laurencin, and J. Rue Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass Bone 49 2011 395 403
55. H. Mirendil, M.-E. Lin, and J. Chun Lysophosphatidic acid (LPA) receptor signaling. Lysophospholipid receptors 2013 John Wiley & Sons, Inc. [p. 1-39]
56. E.J. Goetzl, Y. Kong, and B. Mei Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax J Immunol 162 1999 2049 2056
57. Y. Zheng, J.K. Voice, Y. Kong, and E.J. Goetzl Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes FASEB J 14 2000 2387 2389
58. Y. Zheng, Y. Kong, and E.J. Goetzl Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane J Immunol 166 2001 2317 2322
59. W. Deng, L. Balazs, D.A. Wang, L. Van Middlesworth, G. Tigyi, and L.R. Johnson Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis Gastroenterology 123 2002 206 216
60. T.E. Holmstrom, C.L. Mattsson, Y. Wang, I. Iakovleva, N. Petrovic, and J. Nedergaard Non-transactivational, dual pathways for LPA-induced Erk1/2 activation in primary cultures of brown pre-adipocytes Exp Cell Res 316 2010 2664 2675
61. E.J. Goetzl, H. Dolezalova, Y. Kong, Y.L. Hu, R.B. Jaffe, and K.R. Kalli Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer Cancer Res 59 1999 5370 5375
62. C.C. Yun, H. Sun, D.S. Wang, R. Rusovici, A. Castleberry, and R.A. Hall LPA(2) receptor mediates mitogenic signals in human colon cancer cells Am J Physiol Cell Physiol 289 2005 C2 C11
63. S. Yu, M.M. Murph, Y. Lu, S. Liu, H.S. Hall, and J. Liu Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells J Natl Cancer Inst 100 2008 1630 1642
64. M.C. Huang, H.Y. Lee, C.C. Yeh, Y. Kong, C.J. Zaloudek, and E.J. Goetzl Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA(2)) Oncogene 23 2004 122 129
65. M.C. Huang, H.Y. Lee, C.C. Yeh, Y. Kong, C.J. Zaloudek, and E.J. Goetzl Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2) Oncogene 23 2004 122 129
66. J. So, J. Navari, F.Q. Wang, and D.A. Fishman Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8 Gynecol Oncol 95 2004 314 322
67. J. So, F.Q. Wang, J. Navari, J. Schreher, and D.A. Fishman LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2) Gynecol Oncol 97 2005 870 878
68. J.M. Hope, F.Q. Wang, J.S. Whyte, E.V. Ariztia, W. Abdalla, and K. Long LPA receptor 2 mediates LPA-induced endometrial cancer invasion Gynecol Oncol 112 2009 215 223
69. S. Lin, S.-J. Lee, H. Shim, J. Chun, and C.C. Yun The absence of LPA receptor 2 reduces the tumorigenesis by Apc(Min) mutation in the intestine Am J Physiol Renal Physiol 299 2010 G1128 G1138
70. G.N. Kiss, S.-C. Lee, J.I. Fells, J. Liu, W.J. Valentine, and Y. Fujiwara Mitigation of radiation injury by selective stimulation of the LPA2 receptor Biochim Biophys Acta 1831 2013 117 125
71. X.Q. Ye, K. Hama, J.J.A. Contos, B. Anliker, A. Inoue, and M.K. Skinner LPA(3)-mediated lysophosphatidic acid signalling in embryo implantation and spacing Nature 435 2005 104 108
72. L.C. Chan, W. Peters, Y. Xu, J. Chun, R.V. Farese, and S. Cases LPA3 receptor mediates chemotaxis of immature murine dendritic cells to unsaturated lysophosphatidic acid (LPA) J Leukoc Biol 82 2007 1193 1200
73. S.K. Dey, H. Lim, S.K. Das, J. Reese, B.C. Paria, and T. Daikoku Molecular cues to implantation Endocr Rev 25 2004 341 373
74. E. Rother, R. Brandl, D.L. Baker, P. Goyal, H. Gebhard, and G. Tigyi Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques Circulation 108 2003 741 747
75. L. Ma, H. Uchida, J. Nagai, M. Inoue, J. Chun, and J. Aoki Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain Mol Pain 5 2009 64
76. Z. Lee, C.-T. Cheng, H. Zhang, M.A. Subler, J. Wu, and A. Mukherjee Role of LPA(4)/p2y9/GPR23 in negative regulation of cell motility Mol Biol Cell 19 2008 5435 5445
77. A.L. Khandoga, Y. Fujiwara, P. Goyal, D. Pandey, R. Tsukahara, and A. Bolen Lysophosphatidic acid-induced platelet shape change revealed through LPA(1-5) receptor-selective probes and albumin Platelets 19 2008 415 427
78. Z. Pamuklar, J.S. Lee, H.Y. Cheng, M. Panchatcharam, S. Steinhubl, and A.J. Morris Individual heterogeneity in platelet response to lysophosphatidic acid - evidence for a novel inhibitory pathway Arterioscler Thromb Vasc Biol 28 2008 555 561
79. K. Yanagida, S. Ishii, F. Hamano, K. Noguchi, and T. Shimizu LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line J Biol Chem 282 2007 5814 5824
80. J.P. Mansell, M. Barbour, C. Moore, M. Nowghani, M. Pabbruwe, and T. Sjostrom The synergistic effects of lysophosphatidic acid receptor agonists and calcitriol on MG63 osteoblast maturation at titanium and hydroxyapatite surfaces Biomaterials 31 2010 199 206
81. K. Kotarsky, A. Boketoft, J. Bristulf, N.E. Nilsson, A. Norberg, and S. Hansson Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes J Pharmacol Exp Ther 318 2006 619 628
82. C.-W. Lee, R. Rivera, S. Gardell, A.E. Dubin, and J. Chun GPR92 as a new G(12/13)- and G(q)-coupled lysophosphatidic acid receptor that increases cAMP, LPA(5) J Biol Chem 281 2006 23589 23597
83. A. Lundequist, and J.A. Boyce LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1 beta release PLoS ONE 6 2011 e18192-e
84. D.Y. Oh, J.M. Yoon, M.J. Moon, J.-I. Hwang, H. Choe, and J.Y. Lee Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92 J Biol Chem 283 2008 21054 21064
85. M.-E. Lin, R.R. Rivera, and J. Chun Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain J Biol Chem 287 2012 17608 17617
86. R.A. Kinloch, and P.J. Cox New targets for neuropathic pain therapeutics Expert Opin Ther Targets 9 2005 685 698
87. A.L. Khandoga, D. Pandey, U. Welsch, R. Brandl, and W. Siess GPR92/LPA(5) lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques Cardiovasc Res 90 2011 157 164
88. S. Lin, S. Yeruva, P. He, A.K. Singh, H. Zhang, and M. Chen Lysophosphatidic acid stimulates the intestinal brush border Na(+)/H(+) exchanger 3 and fluid absorption via LPA(5) and NHERF2 Gastroenterology 138 2010 649 658
89. Y. Shimomura, M. Wajid, Y. Ishii, L. Shapiro, L. Petukhova, and D. Gordon Disruption of P2RY5, an orphan G protein-coupled receptor, underlies autosomal recessive woolly hair Nature Genet 40 2008 335 339
90. K. Kano, N. Arima, M. Ohgami, and J. Aoki LPA and its analogs-attractive tools for elucidation of LPA biology and drug development Curr Med Chem 15 2008 2122 2131
91. G.D. Prestwich, J. Gajewiak, H. Zhang, X. Xu, G. Yang, and M. Serban Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer Biochim Biophys Acta 1781 2008 588 594
92. H. Zhang, X. Xu, J. Gajewiak, R. Tsukahara, Y. Fujiwara, and J. Liu Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo Cancer Res 69 2009 5441 5449
93. R.K. Lynch Kevin, and T.L. Macdonald Structure-activity relationships of lysophosphatidic acid analogs Biochim Biophys Acta 1582 2002 289 294
94. C.E. Heise, W.L. Santos, A.M. Schreihofer, B.H. Heasley, Y.V. Mukhin, and T.L. Macdonald Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist Mol Pharmacol 60 2001 1173 1180
95. G.D. Prestwich, Y. Xu, L. Qian, J. Gajewiak, and G. Jiang New metabolically stabilized analogues of lysophosphatidic acid: agonists, antagonists and enzyme inhibitors Biochem Soc Trans 33 2005 1357 1361
96. J.E. East, K.M. Carter, P.C. Kennedy, N.A. Schulte, M.L. Toews, and K.R. Lynch Development of a phosphatase-resistant, l-tyrosine derived LPA1/LPA3 dual antagonist MedChemComm 2 2011 325 330
97. C.A. Lipinski Lead- and drug-like compounds: the rule-of-five revolution Drug Discov Today Technol 1 2004 337 341
98. D.C. Budd, and Y. Qian Development of lysophosphatidic acid pathway modulators as therapies for fibrosis Future Med Chem 5 2013 1935 1952
99. A.L. Parrill Design of anticancer lysophosphatidic acid agonists and antagonists Future Med Chem 6 2014 871 883
100. A. Ueno, R. Nagao, T. Watanabe, H. Ohta, and M. Yagi Preparation of novel isoxazoles and thiazoles as LPA receptor antagonists and use thereof as remedies 2001 Kirin Beer Kabushiki Kaisha Japan [WO2001060819A1]
101. H. Ohta, K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, and J. Kon Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors Mol Pharmacol 64 2003 994 1005
102. T. Kimura, C. Mogi, K. Sato, H. Tomura, H. Ohta, and D.-S. Im P2y5/LPA6 attenuates LPA1-mediated VE-cadherin translocation and cell-cell dissociation through G12/13 protein-Src-Rap1 Cardiovasc Res 92 2011 149 158
103. M. David, J. Ribeiro, F. Descotes, C.-M. Serre, M. Barbier, and M. Murone Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis Int J Oncol 40 2012 1133 1141
104. T. Sato, K. Sugimoto, A. Inoue, S. Okudaira, J. Aoki, and H. Tokuyama Synthesis and biological evaluation of optically active Ki16425 Bioorg Med Chem Lett 22 2012 4323 4326
105. T. Yamamoto, K. Fujita, S. Asari, A. Chiba, Y. Kataba, and K. Ohsumi Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists Bioorg Med Chem Lett 17 2007 3736 3740
106. Ajinomoto's LPA1 antagonist for fibrotic diseases. In: M PM, editor. American chemical society - 243rd national meeting and exposition (Part II) San Diego, CA, USA; 2011.
107. Structure identified in a non-peer reviewed printed source. Thomson Reuters Cortellis.
108. J. Erikson, J.G. Goddard, and M. Kiefer Methods for detecting compounds which modulate the activity of an LPA receptor 1999 LXR Biotechnology Inc USA [WO9919513A2]
109. J.E. Brittain, T.J. Seiders, and C.D. King Preparation of carbonylamino isoxazolyl biphenylacetic acid derivatives for use as lysophosphatidic acid receptor antagonist 2011 Amira Pharmaceuticals Inc USA [WO2011159550A2]
110. J.E. Brittain, T.J. Seiders, J.H. Hutchinson, C.D. King, and V.W. Rosso Polycyclic LPA1 antagonist and uses thereof 2012 Amira Pharmaceuticals Inc, Bristol-Myers Squibb Company USA [WO2012078805A1]
111. J.H. Hutchinson, I.M. Dearmond, and T.J. Seiders Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions 2011 Amira Pharmaceuticals Inc USA [WO2011159635A1]
112. J.H. Hutchinson, T.J. Seiders, and J.S. Swaney Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye 2011 Amira Pharmaceuticals Inc USA [WO2011159632A1]
113. T.J. Seiders, and J.H. Hutchinson Inhalable formulations of lysophosphatidic acid receptor antagonists 2011 Amira Pharmaceuticals Inc USA [WO2011159633A1]
114. N.E. Santos, and V.R. Lopez Methods for treating spinal cord injury with lysophosphatidic acid (LPA) receptor antagonists 2013 Bristol-Myers Squibb Company USA [WO2013070879A1]
115. S. An, C. Li, G. Zhou, and C. Huang Isoxazolylcarbamate derivatives as lysophosphatidic acid receptor antagonists and their preparation and use for the treatment of LPA receptor-associated diseases 2012 Curegenix Inc. Peop. Rep. China [WO2012100436A1]
116. S.D. Gabriel, M.M. Hamilton, Y. Qian, and A. Sidduri Preparation of pyrazole compounds as lysophosphatidic acid as (LPA) antagonists 2013 F. Hoffmann-La Roche AG, Hoffmann-La Roche Inc. Switz. [WO2013189862A1]
117. S.D. Gabriel, M.M. Hamilton, Y. Qian, and A. Sidduri Preparation of N-aryltriazole compounds as lysophosphatidic acid (LPA) antagonists 2013 F. Hoffmann-La Roche AG, Hoffmann-La Roche Inc. Switz. [WO2013189865A1]
118. S.D. Gabriel, M.M. Hamilton, M.C. Lucas, Y. Qian, and A. Sidduri Preparation of N-alkyltriazole compounds as as lysophosphatidic acid (LPA) antagonists 2013 F. Hoffmann-La Roche AG, Hoffmann-La Roche Inc. Switz. [WO2013189864A1]
119. Y. Qian, M. Hamilton, A. Sidduri, S. Gabriel, Y. Ren, and R. Peng Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts J Med Chem 55 2012 7920 7939
120. D. Budd, Y. Qian, R.C. Schoenfeld, and A. Sidduri Preparation of substituted cyanopyrazole compounds as lysophosphatidic acid (LPA) antagonists 2014 F. Hoffmann-La Roche AG, Hoffmann-La Roche Inc. Switz. [WO2014037303A1]
121. A. Sidduri, D.C. Budd, M.E. Fuentes, T. Lambros, Y. Ren, and V. Roongta Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists Bioorg Med Chem Lett 24 2014 4450 4454
122. J.E. Tellew, X. Wang, Y. Wan, Y.F. Xie, S. Pan, and J. Jiang Preparation of phenylethyl pyrazolylcarbamate derivatives as LPA receptor modulators 2012 IRM LLC, Novartis AG Bermuda [WO2012138648A1]
123. B.O. Buckman, J.B. Nicholas, K. Emayan, and S.D. Seiwert Preparation of N-heterocyclylcarbamates as lysophosphatidic acid (LPA) receptor antagonists 2013 InterMune Inc USA [WO2013025733A1]
124. Discovery and anti-fibrotic activity of novel antagonists of lysophosphatidic acid receptor 1 (LPAR1). In: 2014 American thoracic society international conference (ATS). San Diego, California, US; 2014.
125. G. Shankar, D. Solow-Cordero, J.V. Spencer, and C. Gluchowski Methods using Edg receptor modulators for the treatment of Edg receptor-associated conditions 2003 Ceretek LLC USA [WO2003062392A2]
126. M. Terakado, S. Nakade, T. Seko, and Y. Takaoka Preparation of benzamide derivatives as LPA receptor antagonists 2004 Ono Pharmaceutical Co., Ltd Japan [WO2004031118A1]
127. M. Tanaka, S. Nakade, and Y. Takaoka Preparation of aromatic compounds having carboxylic acid moiety as lysophosphatidic acid (LPA) receptor antagonists 2005 Ono Pharmaceutical Co., Ltd Japan [WO2005058790A1]
128. E. Kawaminami, T. Takahashi, T. Kanayama, Y. Fukuda, H. Kaizawa, and Y. Kondoh Preparation of heterocycle carboxamide compounds as lysophosphatidic acid (LPA) receptor antagonists 2011 Astellas Pharma Inc. Japan [WO2011037192A1]
129. E. Kawaminami, T. Takahashi, T. Kanayama, and K. Sakamoto Preparation of heterocycle-carboxamide compounds as LPA receptor antagonists 2012 Astellas Pharma Inc. Japan [WO2012039460A1]
130. M. Schaefer, J. Pernerstorfer, D. Kadereit, H. Strobel, W. Czechtizky, and L.C. Chen Acylamino-substituted fused cyclopentanecarboxylic acid derivatives as EDG-2 receptor inhibitors and their preparation 2009 Sanofi-Aventis, Fr. [WO2009135590A1]
131. J. Pernerstorfer, H.-W. Kleemann, M. Schaefer, A. Safarova, and M. Patek Preparation of acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals 2011 Sanofi-Aventis, Fr. [WO2011053948A1]
132. < http://clinicaltrials.gov/show/NCT01651143 >, [accessed 2014-12-10].
133. Dinesh Khanna CPD, Alexandre Jagerschmidt, Martine Jasson, Oliver Distler, Yannick Allanore. SAR100842, an antagonist of lysophaphatidic acid receptor 1, as a potential treatment for patients with systemic sclerosis: results from a phase 2a study. In: 78th American college of rheumatology annual scientific meeting. Boston, Massachusetts: USA; 2014.
134. 31-Jul-2014, Solid sales and business EPS(1) growth at CER in Q2 2014.
135. 28-Oct-2010, Resilient sales and business EPS1 in Q3 2010 Sanofi-Aventis, Source ID: 1142785.
136. < http://www.sbir.gov/sbirsearch/detail/400200 >, [accessed 2014-12-10].
137. H.P. Beck, T. Kohn, S. Rubenstein, C. Hedberg, R. Schwandner, and K. Hasslinger Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents Bioorg Med Chem Lett 18 2008 1037 1041
138. K. Schiemann, W. Staehle, and D. Wienke Preparation of pyrazolopyridinone derivatives as LPA receptor antagonists 2012 Merck Patent GmbH Germany [WO2012028243A1]
139. K. Schiemann, W. Staehle, M. Busch, D. Wienke, O. Poeschke, and C. Burger Preparation of benzylpiperidine compounds as lysophosphatidic acid (LPA) receptor antagonist 2013 Merck Patent GmbH Germany [WO2013045028A1]
140. W. Staehle, M. Schultz, and K. Schiemann Preparation of N-(benzimidazol-2-yl)cyclopropanecarboxamides as lysophosphatidic acid receptor antagonists 2013 Merck Patent GmbH Germany [WO2013020622A1]
141. G.N. Kiss, J.I. Fells, R. Gupte, S.C. Lee, J. Liu, and N. Nusser Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions Mol Pharmacol 82 2012 1162 1173
142. R. Patil, J. Fells, D.D. Miller, and G. Tigyi Lpa2 receptor-specific benzoic acid derivatives 2014 University of Tennessee Research Foundation USA [WO2014036038A1]
143. R. Patil, J.I. Fells, E. Szabó, K.G. Lim, D.D. Norman, and A. Balogh Design and synthesis of sulfamoyl benzoic acid analogues with subnanomolar agonist activity specific to the LPA2 receptor J Med Chem 57 2014 7136 7140
144. < https://www.sbir.gov/sbirsearch/detail/295496 >, [accessed 2014-12-10].
145. < https://www.medicalcountermeasures.gov/newsroom/2011/protect-against-radiation.aspx >, [accessed 2014-12-10].
146. J.I. Fells, R. Tsukahara, Y. Fujiwara, J. Liu, D.H. Perygin, and D.A. Osborne Identification of non-lipid LPA3 antagonists by virtual screening Bioorg Med Chem Lett 16 2008 6207 6217
147. J.I. Fells, R. Tsukahara, J. Liu, G. Tigyi, and A.L. Parrill Structure-based drug design identifies novel LPA3 antagonists Bioorg Med Chem Lett 17 2009 7457 7464
148. D. Solow-Cordero, G. Shankar, J.V. Spencer, and C. Gluchowski Methods of treating conditions associated with an Edg-7 receptor 2005 SRI International USA [US20050261298A1]
149. S.H. Wong, R. Mallari, M. Graham, L. Atangan, S.-C. Lu, and X. Zhao Strategy for the identification of GPR23/LPA4 receptor agonists and inverse agonists Assay Drug Dev Technol 8 2010 459 470
150. D.H. Kozian, A. Evers, P. Florian, P. Wonerow, S. Joho, and M. Nazare Selective non-lipid modulator of LPA5 activity in human platelets Bioorg Med Chem Lett 22 2012 5239 5243
151. M. Nazare, D. Kozian, A. Evers, and W. Czechtizky Preparation of pyridine derivatives as LPAR5 inhibitors useful in treatment of cardiovascular disorders and other diseases 2013 Sanofi, Fr. [WO2013171316A1]
152. M. Nazare, D. Kozian, A. Evers, and W. Czechtizky Preparation of pyrazole derivatives and their use as LPAR5 antagonists 2013 Sanofi, Fr. [WO2013171317A1]
153. M. Nazare, D. Kozian, M. Bossart, W. Czechtizky, and A. Evers Preparation of benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists 2013 Sanofi, Fr. [WO2013171318A1]
154. E.U. Choi, J.B. Seo, J.Y. Jung, D.S. Shin, T.G. Lee, and J.I. Kim G-protein coupled receptor 92 inhibitors for the treatment of pain and thrombus-related disease 2012 BRNScience Co., Ltd S. Korea [KR2012082226A]
155. V.M. Sardar, D.L. Bautista, D.J. Fischer, K. Yokoyama, N. Nusser, and T. Virag Molecular basis for lysophosphatidic acid receptor antagonist selectivity Biochim Biophys Acta 1582 2002 309 317
156. Y. Fujiwara, V. Sardar, A. Tokumura, D. Baker, K. Murakami-Murofushi, and A. Parrill Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells J Biol Chem 280 2005 35038 35050
157. G. Li, P.D. Mosier, X. Fang, and Y. Zhang Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA4/p2y9/GPR23 receptor: a homology modeling study J Mol Graph Model 28 2009 70 79
158. < http://www.nature.com/nature/focus/gpcrs/ >, [accessed 2014-12-10].